SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision

Author:

Wang Elizabeth Wenqian1,Parchem Jacqueline G2,Atmar Robert L3ORCID,Clark Eva H34ORCID

Affiliation:

1. Department of Infectious Diseases, University of Maryland St. Joseph Medical Center, Towson, Maryland, USA

2. Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA

3. Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

4. Center for Innovations in Quality, Safety, and Effectiveness (IQuESt), Section of Health Services Research, Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, USA

Abstract

Abstract As the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines passed UK and US regulatory milestones in late 2020 and early 2021, multiple professional societies offered recommendations to assist pregnant and breastfeeding people as they choose whether to undergo vaccination. Despite such guidance, the lack of data describing vaccine safety, immunogenicity, and efficacy in pregnant and breastfeeding people has made this decision challenging for many. However, even considering the paucity of data, the known risks of coronavirus disease 2019 during pregnancy likely outweigh the not yet fully elucidated risks of SARS-CoV-2 vaccines, which have reassuring safety and efficacy profiles among nonpregnant people.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference56 articles.

1. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

2. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

4. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19;Stephenson;JAMA,2021

5. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State;Lokken;Am J Obstet Gynecol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3